 CAMBRIDGE, Mass., Nov. 09, 2020 GLOBE NEWSWIRE -- Cue Biopharma, Inc. Nasdaq: CUE, a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patients body, announced today three poster presentations highlighting the Companys clinical and pipeline progress at the Society for Immunotherapy of Cancers 35th Anniversary Annual Meeting SITC 2020. The posters include a clinical update on CUE-101, the lead drug candidate from the IL-2 based CUE-100 series, and data supporting the potential of the Immuno-STATTM Selective Targeting and Alteration of T cells platform to selectively engage and modulate targeted T cells within the body in a manner that can address a broad range of indications. 